자가 세포 치료 시장 규모, 점유율, 동향 분석 보고서 : 치료 유형별, 치료 분야별, 지역별, 부문별 예측(2025-2030년)

Autologous Cell Therapy Market Growth & Trends:

The global autologous cell therapy market size is expected to reach USD 18.23 billion by 2030, registering a CAGR of 22.01% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growing burden of diseases and disorders such as cancer, neurodegenerative disorders, cardiovascular disorders, autoimmune disorders, and orthopedics are the factors driving the demand for the market. Likewise, the reduced risk of autologous cell therapy rejection is one of the important factors for market growth as these therapies are developed from patient-derived cells and support the regeneration of the damaged tissues in the body.

During the COVID-19 pandemic, the market has witnessed various challenges where patients were restricted to stay at home due to safety concerns. Some factors that affected the market growth are manufacturing hurdles and reduced patient inflow in hospitals. However, post-COVID-19 the market has witnessed the demand for the market with FDA clearance and all of the new advances in treating a wide range of disease indications.

In April 2020, Hope Biosciences, a clinical-stage biotechnology company announced the FDA clearance for a phase II clinical trial evaluating the efficacy & safety of HB-adMSCs (Hope Bioscience' autologous, adipose-derived mesenchymal stem cells), to offer immune support against COVID-19. In June 2020, Chiesi Group and Holostem Terapie Avanzate mentioned the agreement for the transfer of the business branch Holoclar. The Holoclar is an autologous stem cell therapy for patients with ocular surface burns. It aims to allow both companies to focus on the strategic objective and accelerate procedures access for rare diseases.

Autologous Cell Therapy Market Report Highlights:

• The non-stem cell therapies segment dominated the market in 2024 with a 97.41% share. This large share can be attributed to several factors, including the expanding CAR T-cell therapy research landscape and increasing clinical trials.
• The oncology segment dominated the market in 2024 with an 88.55% share. CAR T-cells targeting CD19 can help treat Acute Lymphocytic Leukemia (ALL) patients with high rates of full and long-term remission.
• The North America autologous cell therapy market accounted for 57.88% share in 2024. The market is highly competitive since most major players operate in this region, such as BrainStorm Cell Therapeutics and Bristol Myers Squibb.
• Asia Pacific's autologous cell therapy market is anticipated to grow significantly over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Therapeutic Area
  • 1.2.2. Therapy Type
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Autologous Cell Therapy Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising prevalence of chronic and degenerative diseases
    • 3.2.1.2. Reduced risk of autologous cell therapy rejection
    • 3.2.1.3. Growing demand for personalized medicine
    • 3.2.1.4. Increasing investments in research & development
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of therapy and limited affordability
    • 3.2.2.2. Stringent regulatory requirements and long approval timelines
• 3.3. Autologous Cell Therapy Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. COVID-19 Impact Analysis

Chapter 4. Therapy Type Business Analysis

• 4.1. Global Autologous Cell Therapy Market: Therapy Type Segment Dashboard
• 4.2. Global Autologous Cell Therapy Market: Therapy Type Movement Analysis
• 4.3. Global Autologous Cell Therapy Market Estimates and Forecasts, By Therapy Type (USD Million)
• 4.4. Stem Cell Therapies
  • 4.4.1. Stem cell therapies market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. BM, Blood, & Umbilical Cord-derived Stem Cells
    • 4.4.2.1. BM, blood, & umbilical cord-derived stem cells market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Adipose-Derived Cells
    • 4.4.3.1. Adipose-Derived Cells market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Others
    • 4.4.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Non-stem Cell Therapies
  • 4.5.1. Non-stem cell therapies market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.2. T-Cell Therapies
    • 4.5.2.1. T-Cell Therapies market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2.2. CAR T Cell Therapy
      • 4.5.2.2.1. CAR T cell therapy market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2.3. T Cell Receptor (TCR)-based
      • 4.5.2.3.1. T Cell Receptor (TCR)-based market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.3. Others
    • 4.5.3.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Therapeutic Area Business Analysis

• 5.1. Global Autologous Cell Therapy Market: Therapeutic Area Dashboard
• 5.2. Global Autologous Cell Therapy Market: Therapeutic Area Movement Analysis
• 5.3. Global Autologous Cell Therapy Market Estimates and Forecasts, By Therapeutic Area, Revenue (USD Million)
• 5.4. Oncology
  • 5.4.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Cardiovascular Diseases
  • 5.5.1. Cardiovascular diseases market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Musculoskeletal Disorders
  • 5.6.1. Musculoskeletal disorders market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Dermatology
  • 5.7.1. Dermatology market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. Others
  • 5.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8.2. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Regional Business Analysis

• 6.1. Regional Dashboard
• 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. Target disease prevalence
    • 6.3.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Target disease prevalence
    • 6.3.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. Target disease prevalence
    • 6.4.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Target disease prevalence
    • 6.4.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Switzerland
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. Target disease prevalence
    • 6.4.3.5. Switzerland market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Target disease prevalence
    • 6.5.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. Target disease prevalence
    • 6.5.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. India
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. Target disease prevalence
    • 6.5.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.4. South Korea
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Target disease prevalence
    • 6.5.4.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Rest of the World
  • 6.6.1. Rest of the world market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company Categorization
• 7.2. Key Company Position Analysis, 2024
• 7.3. Company Profiles/Listing
  • 7.3.1. Bluebird bio, Inc.
    • 7.3.1.1. Company overview
    • 7.3.1.2. Financial performance
    • 7.3.1.3. Product benchmarking
    • 7.3.1.4. Strategic initiatives
  • 7.3.2. Novartis AG.
    • 7.3.2.1. Company overview
    • 7.3.2.2. Financial performance
    • 7.3.2.3. Product benchmarking
    • 7.3.2.4. Strategic initiatives
  • 7.3.3. Holostem S.R.L
    • 7.3.3.1. Company overview
    • 7.3.3.2. Financial performance
    • 7.3.3.3. Product benchmarking
    • 7.3.3.4. Strategic initiatives
  • 7.3.4. Pharmicell Co. Inc
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Gilead Sciences, Inc. (Kite)
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Product benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Bristol Myers Squibb Company
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Johnson & Johnson (Janssen Global Services, LLC.)
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. JW Therapeutics
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. Vertex Pharamaceuticals Inc.
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. Autolus therapeutics
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Product benchmarking
    • 7.3.10.4. Strategic initiatives